Colleen Kusy
Stock Analyst at Baird
(1.18)
# 2,775
Out of 4,610 analysts
35
Total ratings
36%
Success rate
-14.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $96 → $92 | $27.51 | +234.42% | 9 | Sep 23, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $2.12 | +41.51% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $9.84 | +72.76% | 4 | Aug 8, 2024 | |
| CHRS Coherus BioSciences | Maintains: Outperform | $9 → $8 | $1.04 | +669.23% | 3 | Jul 1, 2024 | |
| OCS Oculis Holding AG | Maintains: Outperform | $35 → $37 | $13.20 | +180.30% | 3 | Jun 11, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | $32 | $27.53 | +16.24% | 1 | Jun 11, 2024 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $50 | $29.15 | +71.53% | 1 | May 2, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $9.61 | +160.15% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $104.93 | +0.07% | 1 | Feb 23, 2024 | |
| AGEN Agenus | Initiates: Outperform | $160 | $4.87 | +3,185.42% | 1 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $0.89 | +1,477.64% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $10.46 | +225.05% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $2.62 | +8,678.29% | 1 | Nov 2, 2021 |
Apellis Pharmaceuticals
Sep 23, 2024
Maintains: Outperform
Price Target: $96 → $92
Current: $27.51
Upside: +234.42%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $2.12
Upside: +41.51%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $9.84
Upside: +72.76%
Coherus BioSciences
Jul 1, 2024
Maintains: Outperform
Price Target: $9 → $8
Current: $1.04
Upside: +669.23%
Oculis Holding AG
Jun 11, 2024
Maintains: Outperform
Price Target: $35 → $37
Current: $13.20
Upside: +180.30%
Enliven Therapeutics
Jun 11, 2024
Initiates: Outperform
Price Target: $32
Current: $27.53
Upside: +16.24%
Spyre Therapeutics
May 2, 2024
Initiates: Outperform
Price Target: $50
Current: $29.15
Upside: +71.53%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.61
Upside: +160.15%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $104.93
Upside: +0.07%
Agenus
Jun 6, 2023
Initiates: Outperform
Price Target: $160
Current: $4.87
Upside: +3,185.42%
Aug 5, 2022
Maintains: Outperform
Price Target: $17 → $14
Current: $0.89
Upside: +1,477.64%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $10.46
Upside: +225.05%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.62
Upside: +8,678.29%